Last reviewed · How we verify
Botox Cosmetic™
Botox Cosmetic blocks acetylcholine release at the neuromuscular junction, paralyzing facial muscles and reducing the appearance of wrinkles.
Botox Cosmetic blocks acetylcholine release at the neuromuscular junction, paralyzing facial muscles and reducing the appearance of wrinkles. Used for Temporary improvement of moderate to severe glabellar lines (frown lines between the brows), Temporary improvement of forehead lines, Temporary improvement of crow's feet (lateral canthal lines).
At a glance
| Generic name | Botox Cosmetic™ |
|---|---|
| Sponsor | Carruthers Dermatology Centre |
| Drug class | Botulinum toxin type A |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin type A binds to SNARE proteins on presynaptic nerve terminals and cleaves SNAP-25, preventing acetylcholine vesicle release. This temporary paralysis of facial muscles smooths dynamic wrinkles caused by repetitive muscle contractions, particularly on the forehead, between the brows, and around the eyes. Effects typically appear within 3–7 days and peak at 2 weeks, lasting approximately 3–4 months.
Approved indications
- Temporary improvement of moderate to severe glabellar lines (frown lines between the brows)
- Temporary improvement of forehead lines
- Temporary improvement of crow's feet (lateral canthal lines)
Common side effects
- Headache
- Injection site pain or bruising
- Eyelid ptosis
- Brow ptosis
- Facial weakness or asymmetry
Key clinical trials
- The Role of Anorectal Manometry in Pediatric Chronic Refractory Constipation (NA)
- Migraine Medication Effects on Urinary Symptoms
- Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder (NA)
- Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) (PHASE1)
- Study to Determine If the Volume Used to Dilute BOTOX Cosmetic™ for Injection Affects Its Overall Effect and Duration. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botox Cosmetic™ CI brief — competitive landscape report
- Botox Cosmetic™ updates RSS · CI watch RSS
- Carruthers Dermatology Centre portfolio CI